Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer

International Journal of Medical Sciences

Volumn 7, Issue 6, 2010, Pages 398-408

  Yassin, Alaa Eldeen B ^a,b   Khalid Anwer, M D ^c   Mowafy, Hammam A ^a   El Bagory, Ibrahim M ^a   Bayomi, Mohsen A ^a,b   Alsarra, Ibrahim A ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

5 fluorouracil; Colon cancer; Double emulsion; Dynasan; Polyvinyl alcohol; Solid lipid nanoparticles

Indexed keywords

BUFFER; ESTER DERIVATIVE; FLUOROURACIL; LIPID; PHOSPHATE; PHOSPHATIDYLCHOLINE; POLYVINYL ALCOHOL; SOLID LIPID NANOPARTICLE; TRIGLYCERIDE ESTER; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DRUG CARRIER; NANOPARTICLE;

ARTICLE; COLON CANCER; DRUG RELEASE; LOCAL THERAPY; NANOENCAPSULATION; PARTICLE SIZE; PH; SLOW DRUG RELEASE; SYNTHESIS; ANIMAL; CHEMISTRY; COLON TUMOR; DIFFERENTIAL SCANNING CALORIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MALE; RAT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DRUG CARRIERS; FLUOROURACIL; LIPIDS; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POLYVINYL ALCOHOL; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 78649671277     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.398     Document Type: Article

References (50)

1. Viñas-Salas J, Biendicho-Palau P, Piñol-Felis C, et al. Calcium inhibits colon carcinogenesis in an experimental model in the rat. Eur J Cancer. 1998; 34: 1941-1945.
2. Davis LE, Krawczeniuk MM. Colorectal Cancer. In: Dipiro JT, ed. Pharmacotherapy a Pathophysiologica Approach. New Jersey, USA: Prentice Hall; 1997: 2513-2538.
3. Rahman Z, Kohli K, Khar R, et al. Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS PharmSciTech. 2006; 7: E47-E53.
4. Shoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanotechnology 2007; 3: 20-31.
5. Park JH, Lee S, Kim JH, et al. Polymeric nanomedicine for cancer therapy. Prog Polym Sci. 2008; 33: 113-137.
6. Sumer B, Gao J. Therapeutic nanomedicine for cancer. Nanomedicine 2008; 3: 137-140.
7. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007; 32: 1054-1082.
8. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999; 47: 125-132.
9. Bellocq NC, Pun SH, Jensen GS, et al. Transferrin-containing cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem. 2003; 14: 1122-1132.
10. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007; 2: 219-232.
11. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005; 65: 5317-5324.
12. Lowery AR, Gobin AM, Day E, et al. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed. 2006; 1: 149-154.
13. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009; 26: 523-580.
14. Peters K, Muller RH. Nanosuspensions for oral administration of poorly soluble drugs; European Symposium on Formulation of Poorly-Available Drugs for Oral Administration. Paris: APGI. 1983: 330-333.
15. Ravi Kumar MNV. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000; 3: 234-258.
16. MacGregor KJ, Embleton JK, Lacy JE, et al. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliver Rev. 1997; 25: 33-46.
17. Muller RH, Mehnert K, Gohla S. Solid lipid nanoparticles (SLN)- an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 1995; 1: 62-69.
18. Muller RH, Weyhers H, zur Mühlen A, et al.: Solid lipid nanoparticles (SLN) - einneuartiger wirkstoff - carrier fur kosmetika und pharmazeutika I. systemeingeschaften, Herstellung und scaling up. Pharm Ind. 1997; 7: 423-427.
19. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles synchrotron radiation x-ray diffraction. Int J Pharm. 1997; 93: 189-199.
20. zur Mühlen A, Njehaus E, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res. 1996; 13: 1411-1416.
21. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998; 45: 149-155.
22. Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004; 58: 673-680.
23. Schmoll HJ, Buchele T, Grothey A, et al. Where do we stand with 5-fluorouracil? Semin Oncol. 1999; 26: 589-605.
24. Calabresi P, Chabner BA. Chemotherapy of neoplastic diseases. In: Limbird JG, Perry LE, Raymond BM, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New Delhi, India: McGraw-Hill; 1996: 1225-1232.
25. Krishnaiah YS, Satyanarayana V, Dinesh Kumar B, et al. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur J Pharm Sci. 2002; 16: 185-192.
26. Philli ps TA, Howell A, Gri eve RJ, et al. Pharmacoki neti cs of oral and intravenous 5-fluorouracil in humans. J Pharm Sci. 1980; 69: 1428-1431.
27. Fraile RJ, Baker LN, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous and by slow infusion. Cancer Res. 1980; 40: 2223-2228.
28. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul. 2008; 25: 289-297.
29. Göppert TM, Müller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm. 2005; 302: 172-186.
30. Yassin AE, Alsarra IA, Alanazi FK, et al. New targeted-colon delivery system: in vitro and in vivo evaluation using x-ray imaging. J Drug Target. 2010; 18: 59-66.
31. Alanazi FK, Yassin A, El-Badry M, et al. Validated high performance liquid chromatographic technique for determination of 5-fluorouracil: applications to stability studies and simulated colonic media. J Chromatogr Sci. 2009; 47: 558-563.
32. Lee JS, Chae GS, An TK, et al. Preparation of 5-fluorouracil-loaded poly(L-lactide-co-glycolide) and evaluation of in vitro release behavior. Macromol Res. 2003; 11: 183-188.
33. Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev. 2007; 59: 379-402.
34. Lee JS, Chae GS, An TK, et al. Preparation of 5-fluorouracil-loaded poly(L-lactide-co-glycolide) wafer and evaluation of in vitro release behavior. Macromol Res. 2003; 11: 183-188.
35. Bunjes H, Koch MHJ, Westesen K. Effect of particle size on colloidal solid triglycerides. Langmuir 2000; 16: 5234-5241.
36. Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003; 92: 1509-1520.
37. Illing A, Unruh T. Investigations on the flow behavior of dispersions of solid triglyceride nanoparticles. Int J Pharm. 2004; 284: 123-131.
38. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci. 2008; 35: 404-416.
39. Liu J, Gong T, Wang C, et al. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007; 340: 153-162.
40. Rahman, Z, Zidan, S, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 2010; 76: 127-137.
41. Yang YW, Lee JS, Kim I, et al. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration. Eur J Pharm Biopharm. 2007; 66: 260-267.
42. Paharia AK, Yadav G, Rai S, et al. Eudragit-coated pectin microspheres of 5-Fluorouracil for colon targeting. AAPS PharmSciTech 2007; 8: E1-E7.
43. Reddy S, Sinha V, Reddy D. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today 1995; 35: 537-580.
44. Hobbs, SK, Monsky, WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U.S.A. 1998; 95: 4607-4612.
45. Sinha VR, Mittal BR, Bhutani KK, et al. Colonic drug delivery of 5-fluorouracil: an in vitro evaluation. Int J Pharm. 2004; 269: 101-108.
46. Sinha VR, Mittal BR, Kumria R. In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery. Int J Pharm. 2005; 289: 79-85.
47. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005; 85: 227-234.
48. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005; 85: 415-420.
49. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990; 11: 465-475.
50. Salyers AA. Molecular and biochemical approaches to determining what bacteria are doing in vivo. Antonie Van Leeuwenhoek 1989; 55: 33-38.